Dabrafenib, Trametinib Active in Pediatric Glioma With BRAF V600

THURSDAY, Sept. 21, 2023 -- Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news